127 related articles for article (PubMed ID: 36993422)
21. Glycosylation pathways in the biosynthesis of gangliosides in melanoma and neuroblastoma cells: relative glycosyltransferase levels determine ganglioside patterns.
Ruan S; Lloyd KO
Cancer Res; 1992 Oct; 52(20):5725-31. PubMed ID: 1394196
[TBL] [Abstract][Full Text] [Related]
22. Anti-GD2 antibody dinutuximab inhibits triple-negative breast tumor growth by targeting GD2
Ly S; Anand V; El-Dana F; Nguyen K; Cai Y; Cai S; Piwnica-Worms H; Tripathy D; Sahin AA; Andreeff M; Battula VL
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33722905
[TBL] [Abstract][Full Text] [Related]
23. CRISPR/Cas9 targeting of GPRC6A suppresses prostate cancer tumorigenesis in a human xenograft model.
Ye R; Pi M; Cox JV; Nishimoto SK; Quarles LD
J Exp Clin Cancer Res; 2017 Jun; 36(1):90. PubMed ID: 28659174
[TBL] [Abstract][Full Text] [Related]
24. Differential expression profiles of glycosphingolipids in human breast cancer stem cells vs. cancer non-stem cells.
Liang YJ; Ding Y; Levery SB; Lobaton M; Handa K; Hakomori SI
Proc Natl Acad Sci U S A; 2013 Mar; 110(13):4968-73. PubMed ID: 23479608
[TBL] [Abstract][Full Text] [Related]
25. Upregulation of Ganglioside GD2 Synthase (GD2S), as a New Putative Cancer Stem Cell Marker in Breast Carcinomas.
Mansoori M; Mirzaei A; Abdi Rad I; Mahmodlou R; Mansouri F; Saeednejad Zanjani L; Asadi-Lari Z; Madjd Z
Med J Islam Repub Iran; 2021; 35():148. PubMed ID: 35321364
[No Abstract] [Full Text] [Related]
26. B4GALNT1 induces angiogenesis, anchorage independence growth and motility, and promotes tumorigenesis in melanoma by induction of ganglioside GM2/GD2.
Yoshida H; Koodie L; Jacobsen K; Hanzawa K; Miyamoto Y; Yamamoto M
Sci Rep; 2020 Jan; 10(1):1199. PubMed ID: 31988291
[TBL] [Abstract][Full Text] [Related]
27. Ganglioside GD2 in reception and transduction of cell death signal in tumor cells.
Doronin II; Vishnyakova PA; Kholodenko IV; Ponomarev ED; Ryazantsev DY; Molotkovskaya IM; Kholodenko RV
BMC Cancer; 2014 Apr; 14():295. PubMed ID: 24773917
[TBL] [Abstract][Full Text] [Related]
28. Oncotargets GD2 and GD3 are highly expressed in sarcomas of children, adolescents, and young adults.
Dobrenkov K; Ostrovnaya I; Gu J; Cheung IY; Cheung NK
Pediatr Blood Cancer; 2016 Oct; 63(10):1780-5. PubMed ID: 27304202
[TBL] [Abstract][Full Text] [Related]
29. Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy.
Nazha B; Inal C; Owonikoko TK
Front Oncol; 2020; 10():1000. PubMed ID: 32733795
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of STAT3 prevents bone metastatic progression of prostate cancer in vivo.
Thulin MH; Määttä J; Linder A; Sterbova S; Ohlsson C; Damber JE; Widmark A; Persson E
Prostate; 2021 Jun; 81(8):452-462. PubMed ID: 33822400
[TBL] [Abstract][Full Text] [Related]
31. Using a combination of gangliosides and cell surface vimentin as surface biomarkers for isolating osteosarcoma cells in microfluidic devices.
Fasanya HO; Dopico PJ; Yeager Z; Fan ZH; Siemann DW
J Bone Oncol; 2021 Jun; 28():100357. PubMed ID: 33912384
[TBL] [Abstract][Full Text] [Related]
32. Ganglioside GD3 is up-regulated in microglia and regulates phagocytosis following global cerebral ischemia.
Wang J; Zhang Q; Lu Y; Dong Y; Dhandapani KM; Brann DW; Yu RK
J Neurochem; 2021 Aug; 158(3):737-752. PubMed ID: 34133773
[TBL] [Abstract][Full Text] [Related]
33. Effect of Oral β-Glucan on Antibody Response to Ganglioside Vaccine in Patients With High-Risk Neuroblastoma: A Phase 2 Randomized Clinical Trial.
Cheung IY; Mauguen A; Modak S; Ragupathi G; Basu EM; Roberts SS; Kushner BH; Cheung NK
JAMA Oncol; 2023 Feb; 9(2):242-250. PubMed ID: 36547975
[TBL] [Abstract][Full Text] [Related]
34. The yes-associated protein (YAP) is associated with resistance to anti-GD2 immunotherapy in neuroblastoma through downregulation of
Pilgrim AA; Jonus HC; Ho A; Cole AC; Shim J; Goldsmith KC
Oncoimmunology; 2023; 12(1):2240678. PubMed ID: 37554309
[TBL] [Abstract][Full Text] [Related]
35. Expression of ganglioside GD2, reprogram the lipid metabolism and EMT phenotype in bladder cancer.
Vantaku V; Donepudi SR; Ambati CR; Jin F; Putluri V; Nguyen K; Rajapakshe K; Coarfa C; Battula VL; Lotan Y; Putluri N
Oncotarget; 2017 Nov; 8(56):95620-95631. PubMed ID: 29221154
[TBL] [Abstract][Full Text] [Related]
36. CRISPR/Cas9-mediated deletion of Interleukin-30 suppresses IGF1 and CXCL5 and boosts SOCS3 reducing prostate cancer growth and mortality.
Sorrentino C; D'Antonio L; Ciummo SL; Fieni C; Landuzzi L; Ruzzi F; Vespa S; Lanuti P; Lotti LV; Lollini PL; Di Carlo E
J Hematol Oncol; 2022 Oct; 15(1):145. PubMed ID: 36224639
[TBL] [Abstract][Full Text] [Related]
37. Quantitation of GD2 synthase mRNA by real-time reverse transcription-polymerase chain reaction: utility in bone marrow purging of neuroblastoma by anti-GD2 antibody 3F8.
Cheung IY; Lo Piccolo MS; Collins N; Kushner BH; Cheung NK
Cancer; 2002 Jun; 94(11):3042-8. PubMed ID: 12115395
[TBL] [Abstract][Full Text] [Related]
38.
McNerney KO; Karageorgos S; Ferry GM; Wolpaw AJ; Burudpakdee C; Khurana P; Toland CN; Vemu R; Vu A; Hogarty MD; Bassiri H
Oncoimmunology; 2022; 11(1):2075204. PubMed ID: 35646475
[TBL] [Abstract][Full Text] [Related]
39. Therapeutic efficacy of antibody-drug conjugates targeting GD2-positive tumors.
Kalinovsky DV; Kibardin AV; Kholodenko IV; Svirshchevskaya EV; Doronin II; Konovalova MV; Grechikhina MV; Rozov FN; Larin SS; Deyev SM; Kholodenko RV
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764367
[TBL] [Abstract][Full Text] [Related]
40. Monoclonal antibodies to disialogangliosides: characterization of antibody-mediated cytotoxicity against human melanoma and neuroblastoma cells in vitro.
Kawashima I; Tada N; Fujimori T; Tai T
J Biochem; 1990 Jul; 108(1):109-15. PubMed ID: 2121721
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
